Skip to main content

GeoVax to Present at the 2024 BIO CEO & Investor Conference

ATLANTA, GA - (NewMediaWire) - February 19, 2024 - Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.

Presentation Details:

Presenter:         David Dodd, Chairman & CEO

Date/Time:        February 26, 2024, 4:15 pm ET

Location:           New York Marriott Marquis

Registration:     BIO CEO & Investor Conference

GeoVax senior management will also conduct one-on-one meetings during the conference. For more information or to schedule a meeting, please visit the conference page here or contact GeoVax Investor Relations.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.


Company Contact: Investor Relations Contact: Media Contact:
info@geovax.com paige.kelly@sternir.com sr@roberts-communications.com 
678-384-7220 212-698-8699 202-779-0929

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.93
-5.10 (-2.30%)
AAPL  260.49
-2.28 (-0.87%)
AMD  230.54
-7.49 (-3.14%)
BAC  50.81
-0.71 (-1.38%)
GOOG  253.35
+2.01 (0.80%)
META  730.82
-2.45 (-0.33%)
MSFT  522.13
+4.47 (0.86%)
NVDA  179.67
-1.49 (-0.82%)
ORCL  270.99
-4.16 (-1.51%)
TSLA  433.31
-9.30 (-2.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.